The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein]
ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] [bafilomycin A1 co-treated with Swainsonine] results in increased expression of ATG5 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of ATG5 protein
bafilomycin A1 results in decreased expression of BCL2 mRNA bafilomycin A1 promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein] [Swainsonine co-treated with bafilomycin A1] results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein] bafilomycin A1 results in increased expression of BECN1 protein
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein] vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein] bafilomycin A1 results in increased expression of BID protein modified form
bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]
bafilomycin A1 results in decreased activity of CASP3 protein bafilomycin A1 results in increased cleavage of CASP3 protein bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein] bafilomycin A1 results in increased activity of CASP3 protein [Swainsonine co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]; bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein] [bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein]
bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein]
bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]
bafilomycin A1 results in increased expression of DDIT4 protein [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium] bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein]
bafilomycin A1 results in increased expression of HIF1A protein HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]
bafilomycin A1 results in decreased expression of HMOX1 protein [bafilomycin A1 co-treated with methanandamide] results in increased expression of HMOX1 protein; [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein]
bafilomycin A1 results in decreased expression of IL1B mRNA [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
[bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 protein bafilomycin A1 results in increased expression of LAMP1 protein
bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of MAP1LC3A protein] bafilomycin A1 results in increased expression of MAP1LC3A protein modified form
[bafilomycin A1 co-treated with Miconazole] results in increased expression of MAP1LC3B protein; [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [metarrestin results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Miconazole results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ovatodiolide results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 results in increased expression of and results in increased lipidation of MAP1LC3B protein; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] bafilomycin A1 results in increased lipidation of MAP1LC3B protein [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] bafilomycin A1 results in increased expression of MAP1LC3B protein modified form [bafilomycin A1 co-treated with Swainsonine] results in increased expression of MAP1LC3B mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [tricalcium phosphate results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] bafilomycin A1 results in increased cleavage of MAP1LC3B protein bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein] bafilomycin A1 results in increased expression of MAPK1 protein modified form
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein] bafilomycin A1 results in increased expression of MAPK3 protein modified form
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 results in decreased phosphorylation of MTOR protein bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein] bafilomycin A1 results in increased expression of NFE2L2 protein
bafilomycin A1 results in increased expression of NLRP3 protein bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein]
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein] bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein] bafilomycin A1 results in increased expression of PARP1 protein modified form
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of PRKAA1 protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased phosphorylation of PRKAA1 protein]
[PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]] which affects the abundance of Malondialdehyde; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]
bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]
bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]]
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein] bafilomycin A1 results in increased expression of SNAI1 protein
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein bafilomycin A1 results in increased expression of SNCA protein
bafilomycin A1 results in increased expression of SQSTM1 protein bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein] [Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [metarrestin results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [Miconazole results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] [bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of SQSTM1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; decamethrin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]
bafilomycin A1 results in increased expression of TNF mRNA [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form]
bafilomycin A1 results in increased expression of TOMM20 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein]
[bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]
bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]
[bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein] bafilomycin A1 results in increased expression of VIM protein
beauvericin results in decreased expression of ATP6 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ATP6 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ATP6 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ATP6 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of ATP6 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of ATP6 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of ATP6 mRNA
beauvericin results in decreased expression of ATP8 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ATP8 mRNA; [beauvericin co-treated with enniatins] affects the expression of ATP8 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of ATP8 mRNA
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of COX1 mRNA; [beauvericin co-treated with enniatins] affects the expression of COX1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of COX1 mRNA beauvericin results in decreased expression of COX1 mRNA
beauvericin results in decreased expression of COX3 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of COX3 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of COX3 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of COX3 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of COX3 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of COX3 mRNA
beauvericin results in decreased expression of ND2 mRNA beauvericin results in increased expression of ND2 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND2 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND2 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND2 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND2 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND2 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in increased expression of ND2 mRNA
beauvericin results in decreased expression of ND3 mRNA beauvericin results in increased expression of ND3 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND3 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND3 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in increased expression of ND3 mRNA
beauvericin results in decreased expression of ND4 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ND4 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND4 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of ND4 mRNA
beauvericin results in decreased expression of ND4L mRNA beauvericin results in increased expression of ND4L mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND4L mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND4L mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND4L mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND4L mRNA
beauvericin results in decreased expression of ND5 mRNA beauvericin results in increased expression of ND5 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND5 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND5 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND5 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND5 mRNA
beauvericin results in decreased expression of ND6 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ND6 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND6 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND6 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND6 mRNA
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of OSGIN1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of OSGIN1 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of OSGIN1 mRNA beauvericin results in increased expression of OSGIN1 mRNA
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of SRXN1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of SRXN1 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of SRXN1 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of SRXN1 mRNA beauvericin results in decreased expression of SRXN1 mRNA
beauvericin results in increased expression of TXNIP mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of TXNIP mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of TXNIP mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of TXNIP mRNA beauvericin results in decreased expression of TXNIP mRNA
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of UCP2 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of UCP2 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of UCP2 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of UCP2 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of UCP2 mRNA beauvericin results in decreased expression of UCP2 mRNA
[Egtazic Acid co-treated with Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone] inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species]
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [AQP9 protein results in increased uptake of Lactic Acid]; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [AQP9 protein results in increased uptake of Selenious Acid]
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone promotes the reaction [CDKN1B protein binds to CDK4 protein] Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of CDKN1B protein
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein [Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical]; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Superoxides]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT protein]
ATM protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PINK1 protein binds to ATM protein] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of ATM protein
Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein] BECN1 protein inhibits the reaction [BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PINK1 protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of BNIP3L protein BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4 protein]; BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Testosterone results in increased cleavage of CASP3 protein] DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]; PGAM5 protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form]
DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]; DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of DNM1L protein modified form
[Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and affects the localization of PINK1 protein] promotes the reaction [FKBP5 protein binds to PINK1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of LDHA protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased susceptibility to LEP protein
BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and affects the localization of MFN2 protein
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of ND1 protein Deoxyglucose inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of ND1 protein]
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]
PINK1 gene mutant form inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PINK1 protein]; PINK1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with PRKN protein] results in increased expression of PINK1 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and affects the localization of PINK1 protein] promotes the reaction [FKBP5 protein binds to PINK1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PINK1 protein binds to ATM protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and affects the localization of PINK1 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and results in increased phosphorylation of PINK1 protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of PINK1 protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased stability of PINK1 protein
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of PKM protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein PRKN gene mutant form results in increased susceptibility to Carbonyl Cyanide m-Chlorophenyl Hydrazone PRKN protein results in decreased susceptibility to Carbonyl Cyanide m-Chlorophenyl Hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the expression of PRKN protein alternative form Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of PRKN protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; Acetylcysteine inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; PARK7 gene mutant form promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; PINK1 gene mutant form inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; PINK1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with PRKN protein] results in increased expression of PINK1 protein; BECN1 protein inhibits the reaction [BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [AMBRA1 protein binds to PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PIK3C3 protein binds to PRKN protein]; Tretinoin affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the expression of PRKN protein alternative form]
[Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC2A1 protein]
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SQSTM1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Testosterone results in increased expression of TNF mRNA] Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]
Deferoxamine results in increased activity of ACO1 protein Deferoxamine results in increased expression of ACO1 protein [Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein
Deferoxamine results in decreased activity of ACP5 protein Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein]
Deferoxamine results in decreased expression of ACTA2 protein Deferoxamine results in increased expression of ACTA2 mRNA Deferoxamine inhibits the reaction [Artesunate results in decreased expression of ACTA2 mRNA]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein] [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]
Deferoxamine results in decreased expression of ALDH3A1 mRNA Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]
Deferoxamine results in decreased expression of ALPL mRNA Indomethacin promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]; Sulindac promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ANXA3 protein] Deferoxamine results in decreased expression of ANXA3 protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]
Deferoxamine binds to APP 5' UTR [Deferoxamine binds to APP 5' UTR] which results in decreased expression of APP protein; [Deferoxamine binds to APP 5' UTR] which results in decreased secretion of APP protein modified form; Deferoxamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]
Deferoxamine results in decreased expression of ARHGDIA protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ARHGDIA protein]
Deferoxamine results in increased activity of ARNT protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA] Deferoxamine results in increased expression of ARNT mRNA
Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA]
Deferoxamine results in increased expression of ATP7A mRNA cupric chloride promotes the reaction [Deferoxamine results in increased expression of ATP7A mRNA]; Deferoxamine promotes the reaction [cupric chloride results in increased expression of ATP7A protein]
[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA]
Deferoxamine results in increased expression of BAX mRNA; Deferoxamine results in increased expression of BAX protein Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of BAX mRNA] [Cisplatin co-treated with Deferoxamine] results in increased expression of BAX protein; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX protein; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BAX protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein]
Deferoxamine results in increased expression of BBC3 mRNA [Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased expression of BCL2 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in decreased expression of BCL2 mRNA] Deferoxamine results in decreased expression of BCL2 mRNA [Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]
Deferoxamine results in increased expression of BCL2L15 mRNA [Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA]
Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of BECN1 protein]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BECN1 protein]
[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA]
Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]] Deferoxamine results in decreased expression of BMP6 mRNA
Deferoxamine results in increased expression of BNIP3 mRNA [Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA]
Deferoxamine results in increased expression of BNIP3L mRNA [Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA]
Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of C5 protein]; Deferoxamine inhibits the reaction [Asbestos, Serpentine results in increased cleavage of C5 protein]
Deferoxamine results in increased expression of CASP3 protein Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein] Deferoxamine results in increased activity of CASP3 protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Deferoxamine promotes the reaction [manganese chloride results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein] Deferoxamine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in increased secretion of CASP3 protein]; Deferoxamine inhibits the reaction [Manganese results in increased activity of CASP3 protein]
Deferoxamine results in increased activity of CASP8 protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased activity of CAT protein]; Deferoxamine inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein] [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CAT mRNA
Deferoxamine inhibits the reaction [[Lipopolysaccharides co-treated with Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein]
Deferoxamine results in increased expression of CDKN1A mRNA; Deferoxamine results in increased expression of CDKN1A protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA] Deferoxamine results in decreased expression of CDKN1A protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1B mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA]
[Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Acetaminophen results in decreased activity of CKB protein]; [Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Carbon Tetrachloride results in decreased activity of CKB protein]
[Oxygen deficiency co-treated with Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] affects the localization of CTNNB1 protein; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of CTNNB1 protein]
Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA]
[Deferoxamine co-treated with Benzene] results in increased expression of CYBB protein; Deferoxamine inhibits the reaction [Benzene results in increased expression of CYBB mRNA]
[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA] Deferoxamine results in increased expression of CYCS mRNA
Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA] Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]
Deferoxamine results in increased expression of DIABLO mRNA [Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA]
Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein] [Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA]
Deferoxamine inhibits the reaction [EPAS1 protein results in increased degradation of COX4I1 protein] Deferoxamine results in increased expression of EPAS1 protein Deferoxamine results in increased stability of EPAS1 protein
Deferoxamine results in increased expression of EPO mRNA Deferoxamine deficiency results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO mRNA Deferoxamine deficiency results in increased stability of EPO mRNA Deferoxamine results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO protein Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein]
Deferoxamine results in decreased expression of ERP29 protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ERP29 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]
[Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of FASN protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of FASN protein]
Deferoxamine results in decreased expression of FECH protein ferric chloride inhibits the reaction [Deferoxamine results in decreased expression of FECH protein]
[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA]
Deferoxamine results in decreased expression of FTH1 protein Deferoxamine inhibits the reaction [Benzene results in increased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [Iron-Dextran Complex results in increased expression of FTH1 protein] Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in decreased expression of FTH1 protein] [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]] Deferoxamine inhibits the reaction [Benzene results in increased expression of FTL1 protein] Deferoxamine results in decreased expression of FTL1 protein
Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]
Deferoxamine results in decreased expression of GAPDH protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GAPDH protein]
Deferoxamine results in increased expression of GLO1 protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GLO1 protein]
GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]]
Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 protein]; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of GPX4 protein] Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]
Deferoxamine inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein] Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of GSK3B protein] Deferoxamine results in decreased phosphorylation of GSK3B protein
Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]] Deferoxamine results in decreased expression of HAMP protein Deferoxamine affects the expression of HAMP mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Doxorubicin co-treated with Deferoxamine] results in increased expression of HIF1A protein; [Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA; [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Arsenic Trioxide promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; Cadmium inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A protein]]; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Deferoxamine results in increased expression of and results in increased stability of HIF1A protein; Deferoxamine results in increased stability of and results in increased expression of HIF1A protein; dihydrotanshinone I inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ST6GAL1 protein promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein] Deferoxamine results in increased expression of HIF1A mRNA; Deferoxamine results in increased expression of HIF1A protein Deferoxamine results in increased stability of HIF1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein] Deferoxamine results in increased activity of HIF1A protein [Deferoxamine results in increased activity of HIF1A protein] which results in decreased susceptibility to Carmustine Deferoxamine results in decreased degradation of HIF1A protein Deferoxamine affects the localization of HIF1A protein
Deferoxamine results in increased expression of HK2 protein Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 protein]]; Doxorubicin inhibits the reaction [Deferoxamine results in increased expression of HK2 protein]
Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides] Deferoxamine results in decreased degradation of HMOX1 protein Deferoxamine results in decreased expression of HMOX1 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Fenretinide results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]] Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; Deferoxamine inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPA1A protein] Deferoxamine results in decreased expression of HSPA1A protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA; ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPD1 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA] Deferoxamine results in decreased expression of HSPD1 protein
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]
Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; ferric chloride inhibits the reaction [Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]] Deferoxamine results in increased expression of IL1B mRNA Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL1B protein] Deferoxamine results in decreased expression of IL1B mRNA
Deferoxamine inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of and results in increased secretion of IL6 protein]; Deferoxamine inhibits the reaction [Coal Ash results in increased expression of IL6 protein] Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of IL6 protein]; Deferoxamine inhibits the reaction [Asbestos, Amphibole results in increased expression of IL6 mRNA]
Deferoxamine results in increased expression of IREB2 protein Deferoxamine results in increased activity of IREB2 protein Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]; Deferoxamine results in increased expression of and results in increased activity of IREB2 protein
Deferoxamine results in decreased expression of ITGB3 mRNA Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]
[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA]
Deferoxamine affects the reaction [Magnetite Nanoparticles results in increased expression of LCN2 mRNA]; Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein] Deferoxamine results in increased expression of LCN2 mRNA
Deferoxamine results in increased expression of LDHA mRNA Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA protein]]
Deferoxamine results in increased expression of MAP1LC3B protein Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]
Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK1 protein] Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]] [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein] Deferoxamine results in increased phosphorylation of MAPK1 protein
Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK3 protein] Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]] [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein] Deferoxamine results in increased phosphorylation of MAPK3 protein
Deferoxamine results in increased phosphorylation of MAPK8 protein Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein]
Deferoxamine results in increased phosphorylation of MAPK9 protein Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein]
Nitroprusside inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein]
Deferoxamine results in increased expression of MFF mRNA [Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA]
[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA; Melatonin affects the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA]
[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA] Deferoxamine results in increased expression of MIEF2 mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR184 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]
[Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]
Calcium Chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of MMP2 protein]; ferric chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA]
Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA] [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA] Deferoxamine results in decreased expression of MMP9 mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA]
Deferoxamine results in increased degradation of MYC protein Deferoxamine results in decreased expression of MYC protein [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA
Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of NCOA4 protein]; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of NCOA4 protein]
Deferoxamine results in increased expression of NDRG1 mRNA; Deferoxamine results in increased expression of NDRG1 protein NDRG1 protein results in decreased susceptibility to Deferoxamine
Deferoxamine inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]] Deferoxamine inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]
Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine] [Deferoxamine results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide
Deferoxamine results in decreased expression of NQO1 mRNA Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]
[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA] Deferoxamine results in increased expression of OPA1 mRNA
Deferoxamine results in decreased expression of P4HA1 protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of P4HA1 protein]
Deferoxamine results in increased cleavage of PARP1 protein Indomethacin promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]; Sulindac promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]
Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein]
Deferoxamine results in increased expression of PDHB protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PDHB protein]
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PGK1 protein] Deferoxamine results in increased expression of PGK1 mRNA Deferoxamine results in decreased expression of PGK1 protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA]
[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA]
Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA]
[Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein]
Deferoxamine results in increased expression of PMAIP1 mRNA [Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA]
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PPIA protein] Deferoxamine results in decreased expression of PPIA protein
Deferoxamine results in increased stability of PTGS2 protein Deferoxamine results in increased expression of PTGS2 mRNA; Deferoxamine results in increased expression of PTGS2 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; [Sulindac co-treated with Deferoxamine] results in increased expression of PTGS2 protein; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Indomethacin promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Deferoxamine inhibits the reaction [Benzene results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]
Deferoxamine results in decreased expression of RACK1 protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of RACK1 protein]
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]
[Deferoxamine co-treated with Manganese] results in increased expression of SLC11A2; [Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein]] which results in increased uptake of Copper; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 mRNA]; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein] Deferoxamine results in decreased expression of SLC11A2 mRNA Deferoxamine results in increased expression of SLC11A2 protein [Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [Deferoxamine results in increased expression of SLC11A2 protein] which results in increased uptake of Manganese; Deferoxamine promotes the reaction [Deferoxamine results in increased expression of SLC11A2 protein]
[Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of SLC2A1 protein; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 protein]] Deferoxamine results in increased expression of SLC2A1 mRNA
Deferoxamine results in increased expression of SLC40A1 protein Deferoxamine inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]
Deferoxamine results in decreased expression of SLC7A11 mRNA Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of SLC7A11 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA] Deferoxamine inhibits the reaction [Benzene results in decreased expression of SLC7A11 mRNA]; Deferoxamine promotes the reaction [Benzene results in decreased expression of SLC7A11 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]
[Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD2 mRNA; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein] Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]
Deferoxamine results in increased expression of SQSTM1 protein [Copper co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]
[Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of SREBF1 protein]
Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein]
Deferoxamine results in increased expression of TFRC mRNA; Deferoxamine results in increased expression of TFRC protein Deferoxamine inhibits the reaction [Doxorubicin results in decreased expression of TFRC mRNA] [Deferoxamine co-treated with Benzene] results in increased expression of TFRC protein; Deferoxamine affects the reaction [Magnetite Nanoparticles results in decreased expression of TFRC mRNA]; Deferoxamine promotes the reaction [Busulfan results in decreased expression of TFRC protein] [Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of TFRC protein
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNF mRNA; Deferoxamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine results in decreased activity of TNF protein] Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of TNF protein] Deferoxamine results in increased susceptibility to TNF protein Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TNF protein]; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine] Deferoxamine results in decreased expression of TNF mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]
[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [sodium bichromate results in increased expression of TP53 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein] Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TP53 mRNA] Deferoxamine results in increased expression of TP53 protein TP53 protein results in decreased susceptibility to Deferoxamine
Deferoxamine results in decreased expression of TPD52L1 protein ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of TPD52L1 protein]
Deferoxamine results in decreased expression of TRAP1 mRNA; Deferoxamine results in decreased expression of TRAP1 protein TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein]
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 protein]
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of VDAC2 protein] Deferoxamine results in decreased expression of VDAC2 protein
Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein] Deferoxamine results in increased expression of VEGFA mRNA Deferoxamine results in increased expression of VEGFA mRNA; Deferoxamine results in increased expression of VEGFA protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Potassium Dichromate results in increased expression of VEGFA protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA] Deferoxamine results in increased secretion of VEGFA protein
[beauvericin co-treated with enniatins] results in decreased expression of MRPL12 mRNA; [Plant Extracts co-treated with enniatins] results in decreased expression of MRPL12 mRNA
enniatins results in decreased expression of ATP6 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ATP6 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ATP6 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ATP6 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of ATP6 mRNA
enniatins results in decreased expression of ATP8 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ATP8 mRNA; [beauvericin co-treated with enniatins] affects the expression of ATP8 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with enniatins] results in decreased expression of ATP8 mRNA
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of COX1 mRNA; [beauvericin co-treated with enniatins] affects the expression of COX1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with enniatins] results in decreased expression of COX1 mRNA enniatins results in decreased expression of COX1 mRNA
enniatins results in decreased expression of COX3 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of COX3 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of COX3 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of COX3 mRNA
enniatins results in decreased expression of ND2 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND2 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND2 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND2 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND2 mRNA
enniatins results in decreased expression of ND3 mRNA enniatins results in increased expression of ND3 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND3 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND3 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with enniatins] results in increased expression of ND3 mRNA
enniatins results in decreased expression of ND4 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ND4 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND4 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with enniatins] results in increased expression of ND4 mRNA
enniatins results in decreased expression of ND4L mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND4L mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND4L mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND4L mRNA
enniatins results in decreased expression of ND5 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND5 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND5 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND5 mRNA
enniatins results in decreased expression of ND6 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ND6 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND6 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND6 mRNA
enniatins results in increased expression of OSGIN1 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of OSGIN1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of OSGIN1 mRNA
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of SRXN1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of SRXN1 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of SRXN1 mRNA
enniatins results in increased expression of TXNIP mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of TXNIP mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of TXNIP mRNA; [Plant Extracts co-treated with enniatins] results in increased expression of TXNIP mRNA
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of UCP2 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of UCP2 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of UCP2 mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA
Ionomycin results in decreased expression of ADM mRNA Ionomycin results in decreased expression of ADM mRNA; Ionomycin results in decreased expression of ADM protein [Ionomycin co-treated with Lipopolysaccharides] results in decreased expression of ADM protein
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of AHR mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and affects the localization of AHR protein
[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PX-866 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; STO 609 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; W 7 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA Ionomycin results in increased expression of ATF4 protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]
Ionomycin inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] Ionomycin results in increased expression of CALCA mRNA [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; Verapamil inhibits the reaction [[Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein] Ionomycin results in increased expression of CALCA protein
CALR protein results in decreased susceptibility to Ionomycin Ionomycin affects the reaction [CALR protein affects the expression of ACAN mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of BGLAP mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of RUNX2 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SOX9 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SP7 mRNA]
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin promotes the reaction [CAMK2A protein binds to ACTN1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to CDK5R1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to GRIN2B protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP3 protein; Calcium deficiency inhibits the reaction [Ionomycin results in increased activity of CASP3 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP8 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL11 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL2 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 protein; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL4 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL5 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA
Ionomycin results in increased expression of CD69 mRNA [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein
[diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein
Ionomycin results in decreased expression of CD86 protein [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]
Egtazic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein]; Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein; Auranofin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA]
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSF2 protein; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 protein
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DPYD mRNA
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin results in increased phosphorylation of DRD3 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG protein; Tamoxifen inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein] Ionomycin results in increased expression of FOS mRNA 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Ionomycin results in increased expression of FOS mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA]
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA]
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA
Ionomycin results in increased secretion of HEXB protein Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; KN 93 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; ML 7 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]
Curcumin analog inhibits the reaction [Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein]]; Curcumin analog inhibits the reaction [Ionomycin results in increased activity of HIF1A protein]; Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA]
HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA]; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 protein]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; Estradiol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Resveratrol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein] 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [2,4-diaminotoluene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Azathioprine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein]; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein]; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; catechol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; hydroxyhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; quinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Genistein affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA; biochanin A promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; daidzein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; formononetin promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; Genistein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; hexaconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; T0901317 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; tetraconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; triflumizol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] [Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
[Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL1B protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein]
[Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [bis(tri-n-butyltin)oxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Sodium Dodecyl Sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] 1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; 4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dexamethasone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [diethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Formaldehyde co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [isophorone diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mitomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pyrimethamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [sodium bromate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Warfarin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein]; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Go 6976 inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Lenalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter]; norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Quercetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; rottlerin inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; tert-Butyl Alcohol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Zinc Sulfate inhibits the reaction [Ionomycin results in increased expression of IL2 mRNA] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein]
[Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein] 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; bathocuproine sulfonate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; tetrathiomolybdate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2RA protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]] [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; [Toluene 2,4-Diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]
2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein] deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein] Ionomycin results in increased expression of IL6 mRNA
Ionomycin results in increased expression of IL9 mRNA [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of JUN protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of JUN protein]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiopental inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]
[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium; Apamin inhibits the reaction [[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium]
[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein; Clotrimazole inhibits the reaction [[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]
Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA]
1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein] [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] Ionomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK8 protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK8 protein]
Ionomycin results in decreased phosphorylation of MAPT protein Okadaic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of MAPT protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA]
Ionomycin results in increased phosphorylation of MYL9 protein Trifluoperazine inhibits the reaction [Ionomycin results in increased phosphorylation of MYL9 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein; Acetic Acid inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of and results in decreased phosphorylation of NFATC2 protein; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]
[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA] Ionomycin affects the localization of NFATC3 protein
NFE2L2 gene mutant form results in increased susceptibility to Ionomycin [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NFE2L2 protein NFE2L2 protein results in decreased susceptibility to Ionomycin
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased degradation of NFKBIA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA
PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA]
Cyclosporine inhibits the reaction [Ionomycin results in increased expression of PPARGC1A mRNA]; KN 62 affects the reaction [Ionomycin results in increased expression of PPARGC1A mRNA]
PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]
PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein
PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein]
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin]
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Ionomycin inhibits the reaction [[N-(4-hydroxyphenyl)arachidonylamide co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA
Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]]
[Ionomycin co-treated with Phorbol Esters] promotes the reaction [entinostat results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [trichostatin A results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [vorinostat results in increased expression of TNFSF9 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA]
[Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein Ionomycin results in increased activity of TRPM4 protein
Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]] Ionomycin results in increased activity of TRPV1 protein Ionomycin inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; Ionomycin inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA
Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-40)]; Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-42)] Monensin inhibits the reaction [Ketamine results in decreased expression of and results in increased cleavage of APP protein]
Monensin inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Monensin inhibits the reaction [Quercetin results in increased secretion of CSF2 protein]
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]]
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]]
Monensin results in decreased expression of TRPM2 protein alternative form Monensin results in increased expression of TRPM2 protein alternative form Lithium inhibits the reaction [Monensin results in increased expression of TRPM2 protein alternative form]
Nigericin inhibits the reaction [AQP9 protein results in increased uptake of Lactic Acid]; Nigericin inhibits the reaction [AQP9 protein results in increased uptake of Selenious Acid]
[Nigericin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP1 protein; CASP1 protein affects the reaction [Nigericin results in increased secretion of IL1B protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased cleavage of CASP1 protein]] Nigericin results in increased cleavage of CASP1 protein [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of CASP1 protein; Arsenic Trioxide inhibits the reaction [Nigericin results in increased cleavage of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of CASP1 protein]; sodium arsenite inhibits the reaction [Nigericin results in increased cleavage of CASP1 protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of GSDMD protein; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of GSDMD protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased cleavage of GSDMD protein]]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased secretion of IL1B protein; Arsenic Trioxide inhibits the reaction [Nigericin results in increased cleavage of IL1B protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of IL1B protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased secretion of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased secretion of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased expression of IL1B protein]; sodium arsenite inhibits the reaction [Nigericin results in increased cleavage of IL1B protein] Nigericin results in increased secretion of IL1B protein [Nigericin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL1B protein; CASP1 protein affects the reaction [Nigericin results in increased secretion of IL1B protein]; Disulfiram inhibits the reaction [Nigericin results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [Nigericin results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [Nigericin results in increased secretion of IL1B protein]
NLRP3 protein affects the reaction [Nigericin results in increased secretion of IL1B protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased expression of NLRP3 protein]]
PYCARD protein affects the reaction [Nigericin results in increased secretion of IL1B protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased expression of PYCARD protein]]
Okadaic Acid inhibits the reaction [EGF protein results in decreased activity of ACO1 protein]; Okadaic Acid inhibits the reaction [TRH protein results in decreased activity of ACO1 protein]; Okadaic Acid promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ACO1 protein]
Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of AKT1 protein]; Okadaic Acid inhibits the reaction [arsenic trioxide promotes the reaction [AKT1 protein binds to PPP2CA protein]]; Okadaic Acid inhibits the reaction [arsenic trioxide results in decreased phosphorylation of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form] Okadaic Acid results in increased phosphorylation of AKT1 protein Okadaic Acid results in decreased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [Okadaic Acid results in decreased phosphorylation of AKT1 protein]]; Quercetin inhibits the reaction [Okadaic Acid results in decreased phosphorylation of AKT1 protein]
[calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]
[Okadaic Acid co-treated with gambierol] results in increased expression of ATP5F1D protein Okadaic Acid results in decreased expression of ATP5F1D protein
Okadaic Acid affects the localization of BAX protein Quercetin inhibits the reaction [Okadaic Acid results in increased expression of BAX protein] Okadaic Acid results in decreased expression of BAX protein Ursodeoxycholic Acid inhibits the reaction [Okadaic Acid results in increased expression of BAX protein] Okadaic Acid results in increased cleavage of and results in increased activity of BAX protein
Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased expression of BBC3 protein]]; Okadaic Acid inhibits the reaction [Estradiol inhibits the reaction [Benzo(a)pyrene results in increased expression of BBC3 protein]]; Okadaic Acid inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased expression of BBC3 protein]] BBC3 protein affects the susceptibility to Okadaic Acid
Norepinephrine inhibits the reaction [Okadaic Acid results in increased activity of CASP3 protein] Okadaic Acid results in increased expression of CASP3 mRNA; Okadaic Acid results in increased expression of CASP3 protein modified form Quercetin inhibits the reaction [Okadaic Acid results in increased cleavage of CASP3 protein] acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP3 protein]; Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein]]; Okadaic Acid inhibits the reaction [Estradiol inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein]]; Okadaic Acid inhibits the reaction [hydroquinone results in increased cleavage of CASP3 protein]; Okadaic Acid inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein]]; Okadaic Acid results in increased cleavage of and results in increased activity of CASP3 protein
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP8 protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP8 protein]; Okadaic Acid inhibits the reaction [hydroquinone results in increased cleavage of CASP8 protein]; Okadaic Acid results in increased cleavage of and results in increased activity of CASP8 protein Okadaic Acid results in decreased expression of CASP8 mRNA Okadaic Acid results in increased activity of CASP8 protein Okadaic Acid results in increased expression of CASP8 protein modified form
Okadaic Acid inhibits the reaction [hydroquinone results in increased cleavage of CASP9 protein]; Okadaic Acid results in increased cleavage of and results in increased activity of CASP9 protein Okadaic Acid results in increased expression of CASP9 mRNA; Okadaic Acid results in increased expression of CASP9 protein modified form Okadaic Acid results in increased activity of CASP9 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of and results in increased secretion of CCL2 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid] results in increased expression of and results in increased secretion of CCL2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid]; [[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] which results in increased uptake of Calcium] inhibits the reaction [CHRNA7 protein results in decreased susceptibility to Okadaic Acid]; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form]; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein]; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid; JAK2 protein affects the reaction [[PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid]; [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form]; [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein]; [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid; Calcium affects the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid]
Okadaic Acid inhibits the reaction [resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]] Okadaic Acid inhibits the reaction [Daunorubicin results in decreased phosphorylation of CREB1 protein]
Okadaic Acid results in increased phosphorylation of CTNNB1 protein Okadaic Acid results in increased expression of CTNNB1 mRNA Okadaic Acid promotes the reaction [CTNNB1 protein binds to CDH1 protein]; Okadaic Acid promotes the reaction [CTNNB1 protein binds to CTNNBIP1 protein]; Okadaic Acid promotes the reaction [CTNNB1 protein binds to TCF4 protein]; Okadaic Acid results in increased activity of and results in decreased phosphorylation of CTNNB1 protein; Okadaic Acid results in increased expression of and affects the localization of CTNNB1 protein
Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [2,4,5,2',5'-pentachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [2,4,5,2',5'-pentachlorobiphenyl results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [PCB 180 results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [PCB 180 results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [Phenobarbital results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [Phenobarbital results in increased expression of CYP2B1 protein]
CYP3A2 protein results in increased metabolism of and results in increased hydroxylation of and results in increased susceptibility to Okadaic Acid CYP3A4 protein results in increased metabolism of and results in increased hydroxylation of and results in decreased susceptibility to Okadaic Acid CYP3A4 protein results in decreased susceptibility to Okadaic Acid
CYP3A23-3A1 protein results in increased metabolism of and results in increased hydroxylation of and results in decreased susceptibility to Okadaic Acid; Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 protein]; Okadaic Acid inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of CYP3A23-3A1 protein]; Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 protein]; Okadaic Acid inhibits the reaction [2,4,5,2',5'-pentachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,4,5,2',5'-pentachlorobiphenyl results in increased expression of CYP3A23-3A1 protein]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP3A23-3A1 protein]; Okadaic Acid inhibits the reaction [PCB 180 results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [PCB 180 results in increased expression of CYP3A23-3A1 protein]; Okadaic Acid inhibits the reaction [Phenobarbital results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [Phenobarbital results in increased expression of CYP3A23-3A1 protein]
Okadaic Acid inhibits the reaction [Dehydroepiandrosterone results in increased expression of CYP4A1 mRNA]; Okadaic Acid inhibits the reaction [Nafenopin results in increased expression of CYP4A1 mRNA]
Okadaic Acid promotes the reaction [Calcitriol results in decreased expression of CYP7A1 mRNA]; Okadaic Acid promotes the reaction [lithocholic acid acetate results in decreased expression of CYP7A1 mRNA]
Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]
Okadaic Acid inhibits the reaction [EGF protein results in decreased activity of ACO1 protein]; Okadaic Acid inhibits the reaction [EGF protein results in decreased activity of IREB2 protein]
[IL1B protein co-treated with Okadaic Acid] results in decreased expression of ELN mRNA; [Okadaic Acid co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of ELN mRNA; Cycloheximide inhibits the reaction [Okadaic Acid results in decreased expression of ELN mRNA] Okadaic Acid results in decreased expression of ELN mRNA; Okadaic Acid results in decreased expression of ELN protein modified form
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Okadaic Acid results in increased degradation of ESR1 mRNA]; Okadaic Acid inhibits the reaction [Linoleic Acids, Conjugated results in decreased phosphorylation of ESR1 protein]; Okadaic Acid results in increased degradation of and results in decreased expression of ESR1 mRNA Okadaic Acid results in decreased expression of ESR1 protein
Okadaic Acid results in increased expression of FAS mRNA [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of FAS mRNA
Okadaic Acid promotes the reaction [Hydrogen Peroxide results in increased expression of FOS protein] Okadaic Acid results in increased expression of FOS mRNA
Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of FOXO3 protein]]; Okadaic Acid inhibits the reaction [Estradiol inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of FOXO3 protein]]; Okadaic Acid inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of FOXO3 protein]]
Okadaic Acid results in increased expression of GJA1 mRNA [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in decreased expression of GJA1 mRNA
[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form]; [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in decreased susceptibility to Okadaic Acid; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form]; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein]; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form]; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein]; Okadaic Acid inhibits the reaction [resveratrol results in decreased phosphorylation of GSK3B protein] Okadaic Acid results in increased phosphorylation of GSK3B protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [Okadaic Acid affects the phosphorylation of GSK3B protein]]; Lithium Chloride inhibits the reaction [Okadaic Acid affects the phosphorylation of GSK3B protein]; Quercetin inhibits the reaction [Okadaic Acid affects the phosphorylation of GSK3B protein] Okadaic Acid results in increased expression of GSK3B protein; Okadaic Acid results in increased expression of GSK3B protein modified form
[Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of GSTP1 mRNA Okadaic Acid results in increased expression of GSTP1 mRNA
Okadaic Acid results in increased expression of HPRT1 mRNA [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of HPRT1 mRNA
[Okadaic Acid co-treated with gambierol] affects the expression of HSPB1 protein modified form; [Okadaic Acid co-treated with gambierol] results in increased expression of HSPB1 protein Okadaic Acid results in decreased expression of HSPB1 protein Okadaic Acid results in increased expression of HSPB1 protein Okadaic Acid affects the expression of HSPB1 protein modified form
Okadaic Acid inhibits the reaction [IL1B protein results in decreased phosphorylation of RELA protein] Okadaic Acid results in increased secretion of IL1B protein Okadaic Acid results in increased expression of IL1B mRNA [IL1B protein co-treated with Okadaic Acid] results in decreased expression of ELN mRNA Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased expression of IL1B protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in decreased expression of and results in decreased secretion of IL4 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid] results in decreased expression of and results in decreased secretion of IL4 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of and results in increased secretion of IL6 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid] results in increased expression of and results in increased secretion of IL6 protein Okadaic Acid results in increased expression of IL6 mRNA Okadaic Acid results in increased secretion of IL6 protein
Okadaic Acid inhibits the reaction [EGF protein results in decreased activity of IREB2 protein]; Okadaic Acid inhibits the reaction [TRH protein results in decreased activity of IREB2 protein]; Okadaic Acid promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of IREB2 protein]
JAK2 protein affects the reaction [[PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid]
Okadaic Acid inhibits the reaction [Tretinoin results in decreased phosphorylation of JUN protein] Okadaic Acid results in increased expression of JUN mRNA
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of MAP3K5 mRNA
Okadaic Acid results in increased activity of MAPK1 protein Okadaic Acid results in increased phosphorylation of MAPK1 protein Quercetin inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPK1 protein] Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]
Okadaic Acid results in increased activity of MAPK3 protein Quercetin inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPK3 protein] Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]
Okadaic Acid results in increased phosphorylation of and results in increased activity of MAPK7 protein Okadaic Acid results in increased phosphorylation of and results in increased activity of MAPK7 protein; U 0126 inhibits the reaction [Okadaic Acid results in increased phosphorylation of and results in increased activity of MAPK7 protein]
[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; [Okadaic Acid co-treated with immunomycin] results in increased phosphorylation of MAPT protein; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; morroniside inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] Okadaic Acid affects the phosphorylation of MAPT protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lithium Chloride inhibits the reaction [Okadaic Acid affects the phosphorylation of MAPT protein]]; Lithium Chloride inhibits the reaction [Okadaic Acid affects the phosphorylation of MAPT protein]; Okadaic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of MAPT protein]; Quercetin inhibits the reaction [Okadaic Acid affects the phosphorylation of MAPT protein] [Okadaic Acid co-treated with immunomycin] results in increased phosphorylation of MAPT protein; Okadaic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of MAPT protein]; Okadaic Acid inhibits the reaction [Potassium Chloride results in decreased phosphorylation of MAPT protein]
[Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of MGST3 mRNA Okadaic Acid results in increased expression of MGST3 mRNA
anethole inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; Fenretinide inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; Okadaic Acid inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; zerumbone inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]]
Okadaic Acid promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of NTS protein] Okadaic Acid results in decreased activity of NTS protein
Okadaic Acid results in decreased expression of PCBP1 protein [Okadaic Acid co-treated with gambierol] results in decreased expression of PCBP1 protein
Okadaic Acid inhibits the reaction [Nafenopin results in increased activity of PPARA protein]; Okadaic Acid results in increased activity of and results in increased stability of PPARA protein Okadaic Acid results in increased phosphorylation of PPARA protein Okadaic Acid inhibits the reaction [Dehydroepiandrosterone results in decreased phosphorylation of PPARA protein]; Okadaic Acid inhibits the reaction [Dehydroepiandrosterone results in increased activity of PPARA protein]; Okadaic Acid inhibits the reaction [Nafenopin results in decreased phosphorylation of PPARA protein]; Okadaic Acid inhibits the reaction [Nafenopin results in increased activity of PPARA protein mutant form]; Okadaic Acid inhibits the reaction [Nafenopin results in increased activity of PPARA protein]; Okadaic Acid inhibits the reaction [pirinixic acid results in decreased phosphorylation of PPARA protein]
Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of PPP1CA protein] Okadaic Acid results in decreased activity of PPP1CA protein
[Okadaic Acid results in decreased activity of PPP2CA protein] which results in decreased susceptibility to Dexamethasone; morroniside inhibits the reaction [Okadaic Acid results in decreased methylation of and results in increased phosphorylation of and results in decreased activity of [PPP2CA protein binds to PPP2CB protein]]; Okadaic Acid inhibits the reaction [Arsenic Trioxide promotes the reaction [AKT1 protein binds to PPP2CA protein]]; Okadaic Acid results in decreased activity of [PPP2CA protein binds to PPP2CB protein]; Okadaic Acid results in decreased methylation of and results in increased phosphorylation of and results in decreased activity of [PPP2CA protein binds to PPP2CB protein] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in decreased expression of PPP2CA protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of PPP2CA mRNA PPP2CA protein mutant form results in decreased susceptibility to Okadaic Acid
morroniside inhibits the reaction [Okadaic Acid results in decreased methylation of and results in increased phosphorylation of and results in decreased activity of [PPP2CA protein binds to PPP2CB protein]]; Okadaic Acid results in decreased activity of [PPP2CA protein binds to PPP2CB protein]; Okadaic Acid results in decreased methylation of and results in increased phosphorylation of and results in decreased activity of [PPP2CA protein binds to PPP2CB protein]
[Okadaic Acid co-treated with gambierol] results in decreased expression of PRDX5 protein Okadaic Acid results in decreased expression of PRDX5 protein
[calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]
[Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of PTTG1 mRNA Okadaic Acid affects the expression of PTTG1 mRNA
anethole inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; Fenretinide inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; Okadaic Acid inhibits the reaction [IL1B protein results in decreased phosphorylation of RELA protein]; Okadaic Acid inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Okadaic Acid results in increased expression of and affects the localization of RELA protein; pregna-4,17-diene-3,16-dione inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; zerumbone inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid] results in increased expression of RELA protein; Quercetin inhibits the reaction [Okadaic Acid results in increased phosphorylation of RELA protein]
Okadaic Acid inhibits the reaction [SLC19A1 protein results in increased uptake of Methotrexate] Okadaic Acid results in decreased activity of SLC19A1 protein
Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]; Okadaic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of cyanoginosin LR]; Sulfobromophthalein inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]
[Okadaic Acid co-treated with gambierol] results in increased expression of SOD2 protein Okadaic Acid results in decreased expression of SOD2 mRNA Okadaic Acid results in increased expression of SOD2 mRNA
morroniside inhibits the reaction [Okadaic Acid results in increased phosphorylation of and results in increased activity of SRC protein]; Okadaic Acid results in increased phosphorylation of and results in increased activity of SRC protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of STAT1 protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid] results in increased expression of STAT1 protein modified form
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid] results in increased expression of and results in increased secretion of TNF protein; caffeic acid phenethyl ester inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; Calcitriol inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; Quercetin inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; Sulindac inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; Tamoxifen inhibits the reaction [Okadaic Acid results in increased expression of TNF protein] Okadaic Acid results in increased secretion of TNF protein Okadaic Acid results in increased expression of TNF mRNA Okadaic Acid inhibits the reaction [hydroquinone results in increased expression of TNF mRNA]; Okadaic Acid inhibits the reaction [hydroquinone results in increased expression of TNF protein]
Okadaic Acid affects the localization of TP53 protein TRP53 protein affects the susceptibility to Okadaic Acid Okadaic Acid affects the reaction [Estradiol promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]]; Okadaic Acid affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]]; Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]]; Okadaic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]]; Okadaic Acid promotes the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] Okadaic Acid results in decreased expression of TP53 mRNA; Okadaic Acid results in decreased expression of TP53 protein
Okadaic Acid inhibits the reaction [TRH protein results in decreased activity of ACO1 protein]; Okadaic Acid inhibits the reaction [TRH protein results in decreased activity of IREB2 protein]
Okadaic Acid results in decreased expression of TXN protein [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of TXN1 mRNA
[1,25-dihydroxyvitamin D co-treated with Okadaic Acid] promotes the reaction [VDR protein mutant form binds to MED1 protein]; [1,25-dihydroxyvitamin D co-treated with Okadaic Acid] results in increased activity of VDR protein mutant form
[Zinc co-treated with pyrithione] results in increased phosphorylation of and results in increased activity of AKT1 protein; AKT1 protein promotes the reaction [[Zinc co-treated with pyrithione] results in increased phosphorylation of and results in increased activity of GSK3B protein]
[Zinc co-treated with pyrithione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Calcitriol results in increased expression of CD14 protein]]; pyrithione promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Calcitriol results in increased expression of CD14 protein]]
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole inhibits the reaction [[Zinc co-treated with pyrithione] promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]]; 4,5,6,7-tetrabromobenzotriazole inhibits the reaction [[Zinc co-treated with pyrithione] promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]]; [Zinc co-treated with pyrithione] promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]
[Zinc co-treated with pyrithione] results in increased phosphorylation of and results in increased activity of GSK3B protein; AKT1 protein promotes the reaction [[Zinc co-treated with pyrithione] results in increased phosphorylation of and results in increased activity of GSK3B protein]; GSK3B protein promotes the reaction [[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein]
[Zinc co-treated with pyrithione] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Calcitriol results in increased expression of ITGAM protein]]; pyrithione promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Calcitriol results in increased expression of ITGAM protein]]
[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein; GSK3B protein promotes the reaction [[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein]
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole inhibits the reaction [[Zinc co-treated with pyrithione] promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]]; 4,5,6,7-tetrabromobenzotriazole inhibits the reaction [[Zinc co-treated with pyrithione] promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]]; [Zinc co-treated with pyrithione] promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]
Calcium Chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein]; ferric chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein]
salinomycin results in increased cleavage of CASP9 protein salinomycin results in increased expression of CASP9 mRNA [salinomycin co-treated with Calcitriol] results in increased expression of CASP9 mRNA
salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of CTNNB1 mRNA] salinomycin results in decreased expression of CTNNB1 mRNA
salinomycin results in decreased activity of CYP3A4 protein salinomycin results in decreased expression of CYP3A4 mRNA CYP3A4 protein results in increased metabolism of salinomycin
salinomycin results in increased expression of DDIT3 mRNA [salinomycin co-treated with Calcitriol] results in increased expression of DDIT3 mRNA; Calcitriol promotes the reaction [salinomycin results in increased expression of DDIT3 mRNA]
[Calcitriol co-treated with salinomycin] results in increased expression of HSPA5 mRNA; Calcitriol promotes the reaction [salinomycin results in increased expression of HSPA5 mRNA]
salinomycin binds to and results in decreased activity of IDO1 protein; salinomycin inhibits the reaction [IFNG protein results in increased expression of IDO1 mRNA]; salinomycin inhibits the reaction [IFNG protein results in increased expression of IDO1 protein]
salinomycin inhibits the reaction [IFNG protein results in increased chemical synthesis of Kynurenine]; salinomycin inhibits the reaction [IFNG protein results in increased expression of IDO1 mRNA]; salinomycin inhibits the reaction [IFNG protein results in increased expression of IDO1 protein]; salinomycin inhibits the reaction [IFNG protein results in increased phosphorylation of JAK1 protein]; salinomycin inhibits the reaction [IFNG protein results in increased phosphorylation of JAK2 protein]; salinomycin inhibits the reaction [IFNG protein results in increased phosphorylation of RELA protein]; salinomycin inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; salinomycin inhibits the reaction [IFNG protein results in increased phosphorylation of STAT3 protein]
[salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA]; [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein]
salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of MMP2 protein] salinomycin results in decreased secretion of MMP2 protein
salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of SNAI1 mRNA]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of SNAI1 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]
salinomycin inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of CTNNB1 mRNA]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of SNAI1 mRNA]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of SNAI1 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of MMP2 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; salinomycin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]
TYMP protein results in decreased susceptibility to salinomycin salinomycin results in increased expression of TYMP mRNA; salinomycin results in increased expression of TYMP protein [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA]; [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein]; [tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA; acetylleucyl-leucyl-norleucinal inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]]; Dactinomycin promotes the reaction [salinomycin results in increased expression of TYMP mRNA]; salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]; SB 203580 inhibits the reaction [salinomycin results in increased expression of TYMP mRNA]; SB 203580 promotes the reaction [[tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA]; tanespimycin inhibits the reaction [Dactinomycin promotes the reaction [salinomycin results in increased expression of TYMP mRNA]]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]]; tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP mRNA]; tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]
browse the term
